A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma
Status:
Completed
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
Allergic bronchopulmonary aspergillosis (ABPA) is a immunological pulmonary disorder caused
by hypersensitive reaction to spores of Aspergillus fumigatus. The prevalence of disease is
about 1-2% in asthmatics and 2-15% in patients with cystic fibrosis. The interest in ABPA
stems from the fact that the disease is glucocorticoid-sensitive and early treatment can
prevent progression to end-stage lung disease. Recently anti-Th2 therapies have been
suggested as treatment for ABPA. Vitamin D has been shown to suppress the Th2 responses and
decrease the levels of Th2 interleukins. Hence, the investigators propose to assess the role
of vitamin D in treating ABPA.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research
Treatments:
Ergocalciferols Glucocorticoids Prednisolone Vitamin D Vitamins